Objev inzulinu v roce 1921 znamenal revoluci v léčbě diabetes mellitus. Od počátečních intravenózních aplikací inzulinu se léčba přesunula k subkutánním injekcím a následně k využití inzulinových per. Významný pokrok přinesly inzulinové pumpy, které umožňují kontinuální subkutánní podávání inzulinu a tím napodobení fyziologické sekrece. Propojení inzulinových pump s kontinuální monitorací glukózy vedlo k vývoji hybridních uzavřených smyček. Tyto systémy využívají algoritmy pro automatickou úpravu dávek inzulinu na základě aktuálních a predikovaných hodnot glykemie. Výsledkem je zlepšení glykemické kontroly, snížení variability glykemie a snížení rizika jak hypoglykemických, tak hyperglykemických epizod.
The discovery of insulin in 1921 revolutionized the treatment of diabetes mellitus. From initial intravenous applications, treatment progressed to subcutaneous injections and subsequently to the use of insulin pens. Insulin pumps represented a significant advancement, enabling continuous subcutaneous insulin infusion and thus mimicking physiological secretion. The combination of insulin pumps with continuous glucose monitoring has led to the development of hybrid closed-loop systems. These systems utilize algorithms to automatically adjust insulin doses based on current and predicted glucose levels. The result is improved glycemic control, reduced glycemic variability, and decreased risk of both hypoglycemic and hyperglycemic episodes.
- MeSH
- Diabetes Mellitus, Type 1 drug therapy blood prevention & control MeSH
- Diabetes Mellitus drug therapy prevention & control MeSH
- Hyperglycemia blood prevention & control MeSH
- Hypoglycemia blood prevention & control MeSH
- Insulin administration & dosage pharmacology therapeutic use MeSH
- Insulin Infusion Systems * MeSH
- Continuous Glucose Monitoring methods instrumentation MeSH
- Humans MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
- Keywords
- dulaglutid,
- MeSH
- Diabetes Mellitus, Type 2 * drug therapy MeSH
- Glucagon-Like Peptides analogs & derivatives pharmacology therapeutic use MeSH
- Weight Loss MeSH
- Hypoglycemic Agents pharmacology therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Obesity * drug therapy MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Case Reports MeSH
- MeSH
- Diabetes Mellitus, Type 2 drug therapy MeSH
- Insulins * therapeutic use MeSH
- Clinical Studies as Topic MeSH
- Cohort Studies MeSH
- Humans MeSH
- Metformin therapeutic use MeSH
- Sitagliptin Phosphate * therapeutic use MeSH
- Statistics as Topic MeSH
- Sulfonylurea Compounds therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Comment MeSH
- Overall MeSH
- MeSH
- Diabetes Mellitus, Type 2 * complications MeSH
- Insulin, Long-Acting administration & dosage MeSH
- Drug Combinations MeSH
- Hyperglycemia drug therapy MeSH
- Hypoglycemia epidemiology chemically induced MeSH
- Humans MeSH
- Liraglutide administration & dosage MeSH
- Metformin administration & dosage MeSH
- Multimorbidity MeSH
- Aged MeSH
- Check Tag
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Case Reports MeSH
- Keywords
- Xultophy,
- MeSH
- Diabetes Mellitus, Type 2 * drug therapy MeSH
- Insulin, Long-Acting administration & dosage MeSH
- Drug Combinations MeSH
- Glycated Hemoglobin drug effects MeSH
- Hypoglycemic Agents MeSH
- Humans MeSH
- Liraglutide administration & dosage MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Case Reports MeSH
